Number of shares and votes in Medivir AB after Directed Share Issue

MVIRRegulatoriskt pressmeddelande31.07.2026 klo 16.00

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments in areas of high unmet medical need, announces the total number of shares and votes after the completion of the directed share issue as resolved by the board of directors on 17 June 2026 and approved by the general meeting on 20 July 2026.

The directed share issue was oversubscribed and included both new and existing investors, including Cicero Fonder, Storebrand Sverige Plus and Storebrand Sverige Småbolag Plus as well as Carl Bennet AB, Hallberg Management AB, LINC AB, and Nordea Småbolagsfond Norden. The share issue primarily intends to finance a new indication for the drug candidate MIV-711: Legg-Calvé-Perthes disease, a rare condition in which the femoral head degenerates in children and for which there is currently no approved drug treatment. Medivir believes MIV-711 has the potential to create significant value in this indication, both for affected patients and for its shareholders.

As of 31 July 2026, the last trading day of the month, the total number of shares in Medivir amounts to 626,487,237, of which 624,037,074 are ordinary shares and 2,450,163 are class C shares. The total number of votes amounts to 624,282,090.3. Each ordinary share carries one (1) vote and each class C share carries one-tenth (1/10) of a vote.

For additional information, please contact:
Jens Lindberg, CEO, Medivir AB
Telephone: +46 72 531 11 17
Email: jens.lindberg@medivir.com

About Medivir
Medivir develops innovative therapies targeting diseases with high unmet medical need. The company’s drug candidates focus on indications where current treatment options are limited or non-existent, offering the potential to deliver meaningful improvements for patients. Medivir’s two lead programs are fostrox, a precision chemotherapy designed to selectively target liver cancer cells while minimizing side effects, and MIV-711, aimed at treating Osteogenesis Imperfecta (Brittle bone disease) and Legg-Calvé-Perthes disease (Perthes disease). Both candidates have blockbuster potential, representing significant value creation opportunities Medivir’s shareholders. Collaborations play a key role in Medivir’s business model, with drug development conducted either in-house or in partnership. Medivir (Nasdaq Stockholm: MVIR) is listed on the Small Cap segment of Nasdaq Stockholm. More information is available at www.medivir.com

About MIV-711
MIV-711 is a potent and selective inhibitor of cathepsin K, the main protease involved in breaking down collagen in bone and cartilage. It has been shown to slow, stop or reverse the progressive degeneration of joints affected by osteoarthritis. By inhibiting cathepsin K and increased/excessive osteoclast activity, MIV-711 has the potential to counteract the excessive bone breakdown seen in patients with Osteogenesis Imperfecta (brittle bone disease). MIV-711 restores the balance between the breakdown of bone with mutated collagen and the formation of new bone with the aim of preventing fractures and bone deformities.